(July 28, 2016) A study published recently in JAMA Oncology showed that CA-125 tests and CT scans are routinely used in ovarian cancer surveillance testing, even though evidence has shown there is no clinical benefit to using these tests. There is no consensus on how to follow a patient in remission from ovarian cancer in … Continued
Dr. Anne Reb at Walter Reed National Military Medical Center is currently looking for participants in her research study for women who have been diagnosed with Stage 3 or 4 ovarian cancer and have completed their primary treatment within the last four months and have no clinical evidence of disease. The study will teach you … Continued
(July 18, 2016) The first randomized phase III clinical trial to compare irinotecan and cisplatin with paclitaxel plus carboplatin in patients with clear cell carcinoma (CCC) of the ovary found no significant survival benefit between the groups. The findings of the study, which was conducted in Japan, were reported in the Journal of Clinical Oncology. … Continued
(July 6, 2016) Gynecologic Oncology recently published a study that found that, although surgery leads to longer survival rates, many ovarian cancer patients are not undergoing surgery, and some are not being treated at all. The researchers analyzed data from more than 210,000 women diagnosed with ovarian cancer in the United States between 2003 and … Continued
Every year cancer researchers and doctors gather at several professional meetings to present and discuss the latest and most important advances in basic, translational and clinical cancer research. OCRF Scientific Advisory Committee member Douglas A. Levine, MD, highlighted research relevant to ovarian cancer patients presented at the American Society of Clinical Oncology (ASCO), as well … Continued
(June 23, 2016) The Journal of Clinical Oncology recently published a study on the role of oral contraceptives (OC) on ovarian cancer prevention. The study, which analyzed data from 21 studies with 5, 584 cases of ovarian cancer, concluded that OC reduced the risk of a variety of invasive ovarian cancers. The risk of developing … Continued
Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meetingby Susan Leighton, Ovarian Cancer Survivor and Research Advocate Since the first time I attended ASCO I have seen the number of abstracts presented about ovarian cancer increase significantly as understanding of the disease has expanded. No longer do we hear the one size fits … Continued
The Capital Ovarian Cancer Organization (C.O.C.O.) was founded in August of 2007, in memory Debi Furnish, who died from ovarian cancer in 2005. Around the same time, another woman from Frankfort, Ellen Liebman, died from the disease. Debi’s sister, Beverly Van Houten, and her friend, Jerri Robinson, decided they needed to raise awareness of the … Continued
(June 20, 2016) Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting by Susan Leighton, Ovarian Cancer Survivor and Research Advocate Since the first time I attended ASCO I have seen the number of abstracts presented about ovarian cancer increase significantly as understanding of the disease has expanded. No longer do we hear … Continued
(June 17, 2016) An OCRFA funded study recently published in Oncogene investigated the role that protein STAT3 plays in the activation and metastasis of ovarian cancer cells. Many women with ovarian cancer develop fluid in the abdomen, which contains cancer cells. Those cells, coupled with a high activation of STAT3, can spread to other areas … Continued
With deep sorrow, Ovarian Cancer Research Alliance mourns the passing of our beloved founder and Chairman Emeritus, Sol Schreiber.
(June 9, 2016) A ten year, OCRFA-funded study has revealed the effect that the human leukocyte antigen (HLA) genes, which help regulate the body’s immune system, have on how the body responds to treatment of epithelial ovarian cancer. The scientists report that women with certain types of HLA may have an increased risk of ovarian … Continued
Get email updates about research news, action alerts, and ways to join the fight.
